Esomeprazole versus pantoprazole for healing erosive oesophagitis

Včev, Aleksandar and Begić, Ivana and Ostojić, Rajko and Jurčić, Dragan and Božić, Dubravko and Soldo, Ivan and Gmajnić, Rudika and Kondža, Goran and Khaznadar, Eyad and Mićunović, Nikola (2006) Esomeprazole versus pantoprazole for healing erosive oesophagitis. Collegium antropologicum, 30 (3). pp. 519-522. ISSN 0350-6134 (Print)

[img]
Preview
PDF
Download (82kB) | Preview

Abstract

The aim of this study was to compare the efficacy of esomeprazole and pantoprazole with regard to healing and relief from gastroesophageal reflux disease-related symptoms. I this multicentre, randomized, single-blind study 180 patients (ITT population) diagnosed with endoscopically proven GERD grade A,B,C received esomeprazole (40 mg once daily (o.d.), n = 90) orpantoprazole (40 mg o.d., n = 90). Healing and relief from GERD-related symptoms were assessed at first and final visit (after 4 or 8 weeks of treatment). Esomeprazole 40 mg provided significantly greater healing than pantoprazole 40 mg after 4 weeks of treatment in patients with EE (77.8% vs. 72.2%). Esomeprazole-treated patients were healed after up to 8 weeks of treatment similar those treated with pantoprazole (92.2% vs. 91.1%). The proportion of heartburn-free days was similar in patients treated with esomeprazole and to those treated with pantoprazole.

Abstract in Croatian

Cilj ovog rada je bio komparirati učinkovitost esomeprazola i pantoprazola u cijeljenju erozivnog ezofagitisa (EE) i nestanku simptoma gastroezofagealne refluksne bolesti (GERB). U ovu multicentričnu, randomiziranu, jednostruko slijepu studiju je bilo uključeno 180 bolesnika s endoskopski dijagnosticiranim GERB-om i dobivali su esomeprazol 40 mg/dan (90 bolesnika) ili pantoprazol 40 mg/dan (90 bolesnika). Nakon 4. i 8. tjedna terapije kontrolirani su radi dokaza cijeljenja EE i nestanka simptoma GERB-a. Esomeprazol bio je statistički značajno učinkovitiji od pantoprazola u cijeljenju EE nakon 4 tjedna liječenja (77.8% nasuprot 72.2%). Nakon 8 tjedana liječenja učinkovitost im je bila podjednaka (92.2% nasuprot 91.1%). Postotak bolesnika bez simptoma GERB-a je bio podjednak nakon 4. i 8. tjedna liječenja u obje skupine.

Item Type: Article
MeSH: Anti-Ulcer Agents - adverse effects - therapeutic use ; Benzimidazoles - adverse effects - therapeutic use ; Gastroesophageal Reflux - classification - drug therapy - physiopathology ; Omeprazole - adverse effects - analogs & derivatives - therapeutic use ; Sulfoxides - adverse effects - therapeutic use ; 2-Pyridinylmethylsulfinylbenzimidazoles ; Aged ; Female ; Humans ; Male ; Middle Aged ; Severity of Illness Index ; Treatment Outcome
Departments: Katedra za internu medicinu
Depositing User: Boris Čičovački
Status: Published
Creators:
CreatorsEmail
Včev, AleksandarUNSPECIFIED
Begić, IvanaUNSPECIFIED
Ostojić, RajkoUNSPECIFIED
Jurčić, DraganUNSPECIFIED
Božić, DubravkoUNSPECIFIED
Soldo, IvanUNSPECIFIED
Gmajnić, RudikaUNSPECIFIED
Kondža, GoranUNSPECIFIED
Khaznadar, EyadUNSPECIFIED
Mićunović, NikolaUNSPECIFIED
Date: September 2006
Date Deposited: 14 Oct 2008
Last Modified: 23 Sep 2011 16:10
Subjects: /
Related URLs:
    URI: http://medlib.mef.hr/id/eprint/471

    Actions (login required)

    View Item View Item

    Downloads

    Downloads per month over past year